Literature DB >> 9219769

Chronic sensory ataxic neuropathy and ophthalmoplegia with oculomotor nerve hypertrophy associated with IgM antibodies against gangliosides containing disialosyl groups.

F Umehara, Y Kore-Eda, T Arime, R Kubota, K Arimura, M Osame.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219769      PMCID: PMC1074167          DOI: 10.1136/jnnp.62.6.673

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome.

Authors:  A Chiba; S Kusunoki; T Shimizu; I Kanazawa
Journal:  Ann Neurol       Date:  1992-06       Impact factor: 10.422

2.  N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome.

Authors:  S Kusunoki; A Chiba; K Kon; S Ando; K Arisawa; A Tate; I Kanazawa
Journal:  Ann Neurol       Date:  1994-05       Impact factor: 10.422

3.  Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.

Authors:  A Chiba; S Kusunoki; H Obata; R Machinami; I Kanazawa
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

  3 in total
  2 in total

Review 1.  Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature.

Authors:  D Marastoni; L Africa; G M Fabrizi; F Giannini; A Peretti; S Bocci; L Insana; S Ferrari; F Ginanneschi; G Zanette
Journal:  J Neurol       Date:  2020-04-28       Impact factor: 4.849

2.  Clinicopathological and virological analyses of familial human T-lymphotropic virus type I--associated polyneuropathy.

Authors:  Hirofumi Sawa; Toshiko Nagashima; Kazuo Nagashima; Toshiya Shinohara; Takayo Chuma; Yukio Mano; Nobutada Tachi; William W Hall
Journal:  J Neurovirol       Date:  2005-04       Impact factor: 2.643

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.